Page last updated: 2024-08-23

daunorubicin and Dysmyelopoietic Syndromes

daunorubicin has been researched along with Dysmyelopoietic Syndromes in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (9.23)	18.7374
1990's	16 (24.62)	18.2507
2000's	17 (26.15)	29.6817
2010's	8 (12.31)	24.3611
2020's	18 (27.69)	2.80

Authors

Authors	Studies
Ahmed, SO; Aljurf, M; Alotaibi, S; Mohty, M; Niederwieser, D; Sanz, J	1
Arnold, C; Batten, LM; Betteridge, S; Canham, J; Cavenagh, J; Dennis, M; Dillon, R; Freeman, SD; Gilkes, A; Hemmaway, C; Hinson, EL; Kleeman, M; Knapper, S; Kottaridis, P; Mehta, P; Othman, J; Overgaard, UM; Potter, N; Russell, NH; Villiers, W; Wilhelm-Benartzi, C; Wych, J	1
de Witte, T; Muus, P	1
Bonmati, C; Campidelli, A; D'Aveni-Piney, M; Divoux, M; Kicki, C; Notarantonio, AB; Pagliuca, S; Roth-Guépin, G; Rubio, MT	1
Fenaux, P; Peterlin, P	1
Sasaki, K	1
Alfayez, M; Daver, N; Kadia, T; Kantarjian, H; Ravandi-Kashani, F	1
Chen, B; Chen, D; Guo, D; Wang, L; Xu, P; Zhu, Y; Zuo, Y	1
Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K	1
Andrews, C; Maze, D; Murphy, T; Sibai, H	1
Bhatnagar, B; Koenig, KL; Sahasrabudhe, KD; Sigmund, AM	1
Arber, DA; Erba, HP	1
Cafaro, A; Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Martinelli, G; Masini, C; Silimbani, P; Simonetti, G	1
Adinolfi, E; Curti, A; De Marchi, E; Di Virgilio, F; Milani, A; Orioli, E; Pegoraro, A; Salvestrini, V	1
Chiang, T; Miller, C; Seabury, R; Triesel, K	1
Cortes, JE; Faderl, S; Hogge, DE; Kolitz, JE; Lancet, JE; Lin, TL; Rizzieri, DA; Ryan, DH; Ryan, RJ; Schiller, GJ; Solomon, SR; Uy, GL; Wieduwilt, MJ	1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA	1
Emadi, A; Faderl, S; Finn, L; Garcia, R; Jacoby, MA; Male, HJ; Powell, BL; Saba, NS; Seiter, K	1
Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC	1
Kim, M; Williams, S	1
Mueller, BU; Pabst, T; Seipel, K	1
Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB	1
Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A	1
Mori, N; Motoji, T; Shiseki, M; Takanashi, M; Tanaka, N; Tsuji, K; Wang, YH	1
Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S	1
Burnett, AK; Dennis, M; Goldstone, A; Hills, RK; McMullin, MF; Milligan, D; Pallis, M; Prentice, A; Russell, N; Sellwood, E; Wheatley, K	1
Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS	1
Allen, SL; Asatiani, E; Feldman, EJ; Kolitz, JE; Lancet, JE; List, AF; Louie, AC; Mayer, LD; Ritchie, EK; Roboz, GJ; Swenson, C	1
Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J	1
Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG	1
Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D	1
Bernell, P; Björkholm, M; Celsing, F; Dahl, IM; Dybedal, I; Gahrton, G; Hast, R; Hellström-Lindberg, E; Lerner, R; Lindberg, G; Linder, O; Löfvenberg, E; Nilsson-Ehle, H; Oberg, G; Ohm, L; Paul, C; Samuelsson, J; Tangen, JM; Tidefelt, U; Turesson, I; Wahlin, A; Wallvik, J; Winquist, I	1
Brandwein, J; Chun, K; Gupta, V; Minden, M; Schuh, A; Wells, R; Yi, QL	1
Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A	1
Baer, MR; Barcos, M; Finlay, E; Pawarode, A; Sait, SN	1
Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Jacobsen, SE; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J	1
Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F	1
Bernell, P; Hast, R; Kimby, E	1
Fukushima, T; Kuriyama, K; Miyazaki, Y; Moriuti, Y; Nagai, K; Tomonaga, M; Yoshida, S	1
Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K	1
Amemiya, Y; Furukawa, Y; Hoshino, M; Imagawa, S; Izumi, T; Kawano, C; Kirito, K; Komatsu, N; Kuribara, R; Miura, Y; Miyazato, A; Muroi, K; Omine, K; Otsuki, T; Shimizu, R; Suzuki, T; Tabata, M; Takahashi, H; Takatoku, M; Terui, Y; Tomizuka, H; Toshima, M; Tsunoda, J; Uchida, M; Yoshida, M	1
Eriksson, M; Hast, R; Jakovleva, K	1
Hagiwara, S; Hirano, N; Miwa, A; Takezako, N; Togawa, A; Yuo, A	1
Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M	1
Aoba, M; Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Matsuzaki, M; Mohri, H; Murata, T; Tanaka, M; Togawa, J	1
Daenen, SM; Löwenberg, B; Ossenkoppele, GJ; Sonneveld, P; van der Holt, B; van der Lelie, J; van Putten, WL; Verdonck, LF; Verhoef, GE; Wijermans, PW	1
Elgie, AW; Lewandowicz, GM; Sargent, JM; Taylor, CG; Williamson, CJ	1
Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T	1
Aivado, M; Aul, C; Gattermann, N; Germing, U; Haas, R; Kobbe, G; Rieth, C; Rong, A	1
Bieri, S; Chapuis, B; Helg, C; Miralbell, R	1
Akiyoshi, K; Eguchi, H; Hara, T; Inada, H; Ishii, E; Koga, H; Matsuzaki, A; Miyazaki, S; Nagatoshi, Y; Nakayama, H; Nibu, K; Okamura, J; Take, H; Tamai, Y; Yanai, F	1
Calasanz, MJ; Gesk, S; Grote, W; Harder, L; Martín-Subero, JI; Novo, FJ; Schlegelberger, B; Schoch, R; Siebert, R	1
Andreeff, M; Brenner, MK; Goodell, MA; Kuehnle, I; Marini, F; Wang, RY; Weidner, D; Wulf, GG	1
Iwakiri, R; Kumakawa, T; Mikoshiba, M; Mori, M; Ohta, M; Tsutsumi, H	1
Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W	1
Farhi, DC; Rosenthal, NS	1
Bär, BM; de Pauw, BE; de Witte, T; Haanen, C	1
Aul, C; Schneider, W	1
Cosson, A; Estienne, MH; Fenaux, P; Lai, JL; Lepelley, P; Preudhomme, C; Zandecki, M	1
Huijgens, PC; Langenhuijsen, MM; Ossenkoppele, GJ; van Geel, BM; Wijermans, PW	1
Ichimaru, M; Jinnai, I; Kuriyama, K; Nonaka, H; Sadamori, N; Tagawa, M; Tokunaga, K; Tomonaga, M; Yoshida, Y	1
Dohy, H; Kyo, T	2
Bennett, JM; Owens, MR	1
Boogaerts, MA; Tricot, G	1

Reviews

11 review(s) available for daunorubicin and Dysmyelopoietic Syndromes

Article	Year
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2022
CPX-351 (vyxeos) in AML. Leukemia & lymphoma, 2020, Volume: 61, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic	2020
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides	2020
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. Genes, 2020, 07-24, Volume: 11, Issue:8 Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis	2020
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6 Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines	2020
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Age Factors; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Mutation; Myelodysplastic Syndromes	2020
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 04-15, Volume: 127, Issue:8 Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine	2021
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes	2018
Myelodysplastic syndromes and acute myeloid leukemias in the elderly. European journal of internal medicine, 2018, Volume: 58 Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Gemtuzumab; Geriatric Assessment; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Staurosporine	2018
Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. International journal of hematology, 2001, Volume: 73, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Growth Disorders; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Male; Methotrexate; Myelodysplastic Syndromes; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Survivors; Treatment Outcome; Vincristine	2001
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia, 1992, Volume: 6 Suppl 2 Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine	1992

Trials

16 trial(s) available for daunorubicin and Dysmyelopoietic Syndromes

Article	Year
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood advances, 2023, 08-22, Volume: 7, Issue:16 Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; United Kingdom	2023
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American journal of hematology, 2020, Volume: 95, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate	2020
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood advances, 2021, 03-23, Volume: 5, Issue:6 Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes	2021
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood, 2017, 06-22, Volume: 129, Issue:25 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome	2017
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia, 2009, Volume: 23, Issue:8 Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult	2009
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British journal of haematology, 2009, Volume: 145, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Cytogenetic Analysis; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate	2009
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult	2011
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome	2012
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 2003, Mar-01, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 2003, Volume: 17, Issue:9 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Rate; Thioguanine	2003
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Dec-01, Volume: 13, Issue:23 Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cadherins; Cyclin-Dependent Kinase Inhibitor p15; Cytidine; Daunorubicin; DNA Methylation; Female; Humans; Kruppel-Like Transcription Factors; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Treatment Outcome	2007
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia, 1994, Volume: 8, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Thioguanine	1994
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica Blood, 1997, Apr-01, Volume: 89, Issue:7 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome	1997
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction	1995
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia, 1999, Volume: 13, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Remission Induction	1999
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia, 2000, Volume: 14, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome	2000

Other Studies

38 other study(ies) available for daunorubicin and Dysmyelopoietic Syndromes

Article	Year
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise? The Lancet. Haematology, 2023, Volume: 10, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2023
A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes. Leukemia research, 2023, Volume: 135 Topics: Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning	2023
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes - Authors' reply. The Lancet. Haematology, 2023, Volume: 10, Issue:11 Topics: Cytarabine; Daunorubicin; Humans; Myelodysplastic Syndromes	2023
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes. The Lancet. Haematology, 2023, Volume: 10, Issue:11 Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2023
Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment. International journal of nanomedicine, 2020, Volume: 15 Topics: Animals; Antibodies, Monoclonal; Apoptosis; Cadmium Compounds; Caspase 3; Daunorubicin; Drug Delivery Systems; Humans; Interleukin-3 Receptor alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Myelodysplastic Syndromes; Quantum Dots; Tellurium; Toxicity Tests; Xenograft Model Antitumor Assays	2020
Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression. Cell death & disease, 2020, 10-18, Volume: 11, Issue:10 Topics: Daunorubicin; Gene Expression; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Isoforms; Receptors, Purinergic P2X7; RNA, Messenger	2020
Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes	2021
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2021
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Blood Cell Count; Critical Care; Cyclophosphamide; Cytarabine; Daunorubicin; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Retrospective Studies; Young Adult	2014
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. European journal of haematology, 2016, Volume: 96, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fluconazole; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Remission Induction; Retrospective Studies; Survival Analysis; Triazoles	2016
Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. Leukemia research, 2009, Volume: 33, Issue:7 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Blast Crisis; Cell Cycle; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult	2009
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult	2010
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome	2003
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer, 2005, May-15, Volume: 103, Issue:10 Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Diseases; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome	2005
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome	2006
Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:2 Topics: Adult; Antineoplastic Agents; Chromosomes, Human, Pair 1; Cytarabine; Daunorubicin; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes	2006
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 1995, Apr-15, Volume: 85, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome	1995
[Allogeneic bone marrow transplantation for two patients with acute myeloid leukemia with trilineage myelodysplasia (T-MDS)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:2 Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Myelomonocytic, Acute; Male; Myelodysplastic Syndromes	1994
[Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:3 Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; DNA; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Retrospective Studies; Vincristine	1998
Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes. Polskie Archiwum Medycyny Wewnetrznej, 1998, Volume: 99, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Daunorubicin; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Myelodysplastic Syndromes; Remission Induction; Thioguanine	1998
A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological re International journal of hematology, 1998, Volume: 67, Issue:4 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Hematopoiesis, Extramedullary; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prednisolone; Preleukemia; Remission Induction	1998
De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22). Internal medicine (Tokyo, Japan), 1999, Volume: 38, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Translocation, Genetic	1999
Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML. Advances in experimental medicine and biology, 1999, Volume: 457 Topics: Acridines; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Cell Survival; Cyclosporine; Daunorubicin; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Tetrahydroisoquinolines; Tumor Cells, Cultured	1999
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. British journal of haematology, 2000, Volume: 110, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Dosage Compensation, Genetic; Female; Follow-Up Studies; Hematopoiesis; Humans; Idarubicin; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Retrospective Studies; Thioguanine; Time Factors	2000
Total body irradiation before allogeneic bone marrow transplantation: is more dose better? International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation	2001
Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. Cancer genetics and cytogenetics, 2001, Volume: 127, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 9; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Isoenzymes; Karyotyping; Leukemia, Myelomonocytic, Acute; Metaphase; Middle Aged; Myelodysplastic Syndromes; Poly-ADP-Ribose Binding Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Thioguanine	2001
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood, 2001, Aug-15, Volume: 98, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzimidazoles; Cell Separation; Child; Child, Preschool; Daunorubicin; Drug Resistance; Female; Humans; Immunophenotyping; Infant; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred NOD; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Transplantation; Neoplasms, Second Primary; Stem Cell Transplantation; Stem Cells; Tumor Cells, Cultured	2001
Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. International journal of hematology, 2002, Volume: 75, Issue:1 Topics: Acute Disease; Age Factors; Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholinesterases; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Japan; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Survival Rate	2002
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia. American journal of clinical pathology, 1991, Volume: 95, Issue:4 Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors	1991
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes. The Netherlands journal of medicine, 1990, Volume: 36, Issue:1-2 Topics: Acute Disease; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Time Factors	1990
Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy? Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Remission Induction; Thioguanine	1990
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients. Clinical and laboratory haematology, 1990, Volume: 12, Issue:1 Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Cytarabine; Daunorubicin; Female; Hemoglobins; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Remission Induction; Survival Rate	1990
Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS. The Netherlands journal of medicine, 1989, Volume: 35, Issue:3-4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies	1989
[Marked dysmyelopoiesis after induction chemotherapy in a case of acute myelomonocytic leukemia (M 4) with t(6; 11)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1989, Volume: 30, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 6; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Translocation, Genetic	1989
Results of aggressive chemotherapy for myelodysplastic syndromes. Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, 1988, Volume: 51, Issue:8 Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine	1988
Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: a preliminary report. Medical and pediatric oncology, 1988, Volume: 16, Issue:2 Topics: Aged; Blood Cell Count; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine	1988
[Intensive chemotherapy of refractory anemia with excess of blasts]. Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:4 Pt 2-2 Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Infusions, Intravenous; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine	1988
The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. British journal of haematology, 1986, Volume: 63, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors	1986